Tinelli Valentina, Cabrini Luca, Fominskiy Evgeny, Franchini Stefano, Ferrante Luca, Ball Lorenzo, Pelosi Paolo, Landoni Giovanni, Zangrillo Alberto, Secchi Antonio
Emergency Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Anaesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy; Università Vita-Salute San Raffaele, Milan, Italy.
J Emerg Med. 2019 Sep;57(3):322-328. doi: 10.1016/j.jemermed.2019.06.033. Epub 2019 Aug 14.
Acute respiratory failure (ARF) is a common cause of presentation to the Emergency Department (ED). High flow nasal cannula (HFNC) has been introduced as an alternative way to administer oxygen.
We performed a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing HFNC with conventional oxygen therapy (COT) and noninvasive ventilation (NIV) exclusively in the ED setting.
Inclusion criteria were: RCTs on adults with ARF admitted to the ED, investigating HFNC vs. COT or other modes of ventilation. Trials that compared HFNC support outside the ED, were published as an abstract, or nonrandomized were excluded.
Four RCTs comparing HFNC with COT and one HFNC to NIV met the criteria. Overall, 775 patients were included. The meta-analysis of the studies comparing HFNC and COT showed no differences in intubation requirement, treatment failure, hospitalization, or mortality. Intolerance was significantly higher with HFNC (risk ratio 6.81 95% confidence interval 1.18-39.19; p = 0.03). In the only available RCT comparing HFNC with NIV, no difference was found for intubation rate, treatment failure, tolerance, and dyspnea.
We did not find any benefit of HFNC compared with COT and NIV in terms of intubation requirement, treatment failure, hospitalization, and mortality; COT was better tolerated.
急性呼吸衰竭(ARF)是急诊科常见的就诊原因。高流量鼻导管(HFNC)已被引入作为一种吸氧的替代方式。
我们对随机对照试验(RCT)进行了系统评价和荟萃分析,专门比较急诊科环境下HFNC与传统氧疗(COT)及无创通气(NIV)的效果。
纳入标准为:关于急诊科收治的成年ARF患者的RCT,研究HFNC与COT或其他通气模式的比较。排除比较急诊科以外HFNC支持情况、以摘要形式发表或非随机的试验。
四项比较HFNC与COT的RCT以及一项HFNC与NIV比较的RCT符合标准。总共纳入775例患者。比较HFNC和COT的研究的荟萃分析显示,在插管需求、治疗失败、住院或死亡率方面没有差异。HFNC的不耐受率显著更高(风险比6.81,95%置信区间1.18 - 39.19;p = 0.03)。在唯一一项比较HFNC与NIV的可用RCT中,插管率、治疗失败、耐受性和呼吸困难方面未发现差异。
在插管需求、治疗失败、住院和死亡率方面,我们未发现HFNC与COT及NIV相比有任何益处;COT的耐受性更好。